NBSE logo

NeuBase Therapeutics (NBSE) Depreciation And Amortization

Annual D&A

$1.26 M
+$687.00 K+119.37%

30 September 2022

3-Year Change

+119.37%
NBSE annual depreciation & amortization is up +119.37% over the past 3 years

All-time High

$1.26 M
NBSE annual depreciation & amortization is currently at an all-time high
Annual Total Expenses$33.32 M
NBSE annual total expenses is $33.32 million
Annual Operating Expenses$33.32 M
NBSE annual total operating expenses is $33.32 million
Annual Net Income-$33.78 M
NBSE annual net profit is -$33.78 million

NBSE Depreciation And Amortization Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly D&A

$250.20 K
-$53.80 K-17.70%

30 September 2023

3-Year Change

-1.65%
NBSE quarterly depreciation & amortization is down -1.65% over the past 3 years

All-time High

$416.90 K
NBSE quarterly depreciation & amortization is currently -39.99% below its historical high of $416.90 thousand
Quarterly Total Expenses$1.59 M
NBSE quarterly total expenses is $1.59 million
Quarterly Operating Expenses$1.59 M
NBSE quarterly total operating expenses is $1.59 million
Quarterly Net Income-$1.82 M
NBSE quarterly net profit is -$1.82 million

NBSE Quarterly D&A Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

TTM D&A

$1.17 M
-$85.30 K-6.78%

30 September 2023

3-Year Change

+103.89%
NBSE TTM depreciation & amortization is up +103.89% over the past 3 years

All-time High

$1.40 M
NBSE TTM depreciation & amortization is currently -16.17% below its historical high of $1.40 million
Annual Total Expenses$33.32 M
NBSE annual total expenses is $33.32 million
Annual Operating Expenses$33.32 M
NBSE annual total operating expenses is $33.32 million
TTM Net Income-$13.73 M
NBSE TTM net profit is -$13.73 million

NBSE TTM D&A Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

NBSE Depreciation And Amortization Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year---
3 y3 years+119.4%-1.6%+103.9%
5 y5 years+883.3%+167.9%+814.6%

NBSE Depreciation And Amortization High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3 years
5 y5 years
alltimeall timeat high-40.0%-16.2%

NeuBase Therapeutics Depreciation And Amortization History

DateAnnualQuarterlyTTM
Sept 2023
-
$250.20 K(-17.7%)
$1.17 M(-6.8%)
June 2023
-
$304.00 K(+1.2%)
$1.26 M(-1.9%)
Mar 2023
-
$300.50 K(-5.7%)
$1.28 M(-8.3%)
Dec 2022
-
$318.70 K(-5.0%)
$1.40 M(+10.9%)
Sept 2022
$1.26 M(+119.4%)
$335.50 K(+2.1%)
$1.26 M(+6.9%)
June 2022
-
$328.70 K(-21.2%)
$1.18 M(+15.6%)
Mar 2022
-
$416.90 K(+129.7%)
$1.02 M(+48.4%)
Dec 2021
-
$181.50 K(-28.7%)
$688.90 K(+19.7%)
Sept 2021
$575.50 K(+105.2%)
$254.40 K(+49.9%)
$575.50 K(+55.2%)
June 2021
-
$169.70 K(+103.7%)
$370.80 K(+59.6%)
Mar 2021
-
$83.30 K(+22.3%)
$232.30 K(+16.9%)
Dec 2020
-
$68.10 K(+37.0%)
$198.80 K(-29.1%)
Sept 2020
$280.50 K(+118.5%)
$49.70 K(+59.3%)
$280.40 K(-303.3%)
June 2020
-
$31.20 K(-37.3%)
-$137.90 K(+3840.0%)
Mar 2020
-
$49.80 K(-66.7%)
-$3500.00(-103.2%)
Dec 2019
-
$149.70 K(-140.6%)
$110.60 K(-13.8%)
Sept 2019
$128.40 K(-88.6%)
-$368.60 K(-322.6%)
$128.30 K(-83.5%)
June 2019
-
$165.60 K(+1.0%)
$779.00 K(-12.7%)
Mar 2019
-
$163.90 K(-2.1%)
$892.40 K(-11.4%)
Dec 2018
-
$167.40 K(-40.7%)
$1.01 M(-10.5%)
Sept 2018
$1.12 M(-3.5%)
$282.10 K(+1.1%)
$1.12 M(-0.4%)
June 2018
-
$279.00 K(+0.2%)
$1.13 M(-0.9%)
Mar 2018
-
$278.50 K(-2.3%)
$1.14 M(-1.2%)
Dec 2017
-
$285.00 K(-0.5%)
$1.15 M(-1.1%)
Sept 2017
$1.17 M(-2.0%)
$286.40 K(-0.9%)
$1.17 M(-1.1%)
June 2017
-
$289.00 K(-1.0%)
$1.18 M(-0.6%)
Mar 2017
-
$291.90 K(-2.2%)
$1.19 M(-0.4%)
Dec 2016
-
$298.40 K(-0.3%)
$1.19 M(+0.1%)
Sept 2016
$1.19 M(+0.8%)
$299.30 K(+1.1%)
$1.19 M(+0.3%)
June 2016
-
$296.10 K(0.0%)
$1.19 M(+1.1%)
Mar 2016
-
$296.10 K(-0.5%)
$1.17 M(+0.1%)
Dec 2015
-
$297.70 K(+0.8%)
$1.17 M(-0.7%)
Sept 2015
$1.18 M
$295.30 K(+4.3%)
$1.18 M(-0.9%)
DateAnnualQuarterlyTTM
June 2015
-
$283.10 K(-4.1%)
$1.19 M(+16.3%)
Mar 2015
-
$295.30 K(-3.4%)
$1.02 M(+36.5%)
Dec 2014
-
$305.60 K(0.0%)
$749.40 K(+60.7%)
Sept 2014
$466.30 K(+411.9%)
$305.60 K(+163.2%)
$466.30 K(+150.2%)
June 2014
-
$116.10 K(+425.3%)
$186.40 K(+102.0%)
Mar 2014
-
$22.10 K(-1.8%)
$92.30 K(+0.7%)
Dec 2013
-
$22.50 K(-12.5%)
$91.70 K(+0.5%)
Sept 2013
$91.10 K(+3.9%)
$25.70 K(+16.8%)
$91.20 K(+4.2%)
June 2013
-
$22.00 K(+2.3%)
$87.50 K(+0.2%)
Mar 2013
-
$21.50 K(-2.3%)
$87.30 K(-0.5%)
Dec 2012
-
$22.00 K(0.0%)
$87.70 K(-0.1%)
Sept 2012
$87.70 K(+5.0%)
$22.00 K(+0.9%)
$87.80 K(+1.2%)
June 2012
-
$21.80 K(-0.5%)
$86.80 K(+1.2%)
Mar 2012
-
$21.90 K(-0.9%)
$85.80 K(+1.3%)
Dec 2011
-
$22.10 K(+5.2%)
$84.70 K(+1.6%)
Sept 2011
$83.50 K(+309.3%)
$21.00 K(+1.0%)
$83.40 K(+0.7%)
June 2011
-
$20.80 K(0.0%)
$82.80 K(+33.5%)
Mar 2011
-
$20.80 K(0.0%)
$62.00 K(+50.5%)
Dec 2010
-
$20.80 K(+2.0%)
$41.20 K(+102.0%)
Sept 2010
$20.40 K(>+9900.0%)
$20.40 K(>+9900.0%)
$20.40 K(>+9900.0%)
June 2010
-
$0.00(0.0%)
$0.00(0.0%)
Mar 2010
-
$0.00(0.0%)
$0.00(0.0%)
Dec 2009
-
$0.00(-100.0%)
$0.00(-100.0%)
Sept 2009
$0.00(-100.0%)
-
-
June 2006
-
-$14.30 K(-200.0%)
$61.50 K(+58.9%)
Mar 2006
-
$14.30 K(-76.7%)
$38.70 K(-37.1%)
Dec 2005
$61.50 K(+23.2%)
$61.50 K(-265.8%)
$61.50 K(+23.2%)
June 2005
-
-$37.10 K(-200.0%)
$49.90 K(-33.5%)
Mar 2005
-
$37.10 K(+181.1%)
$75.00 K(+50.3%)
Dec 2004
$49.90 K(+3.5%)
$13.20 K(-64.0%)
$49.90 K(+36.0%)
Sept 2004
-
$36.70 K(-405.8%)
$36.70 K(>+9900.0%)
June 2004
-
-$12.00 K(-200.0%)
$0.00(-100.0%)
Mar 2004
-
$12.00 K
$12.00 K
Dec 2003
$48.20 K
-
-

FAQ

  • What is NeuBase Therapeutics annual depreciation & amortization?
  • What is the all time high annual D&A for NeuBase Therapeutics?
  • What is NeuBase Therapeutics quarterly depreciation & amortization?
  • What is the all time high quarterly D&A for NeuBase Therapeutics?
  • What is NeuBase Therapeutics TTM depreciation & amortization?
  • What is the all time high TTM D&A for NeuBase Therapeutics?

What is NeuBase Therapeutics annual depreciation & amortization?

The current annual D&A of NBSE is $1.26 M

What is the all time high annual D&A for NeuBase Therapeutics?

NeuBase Therapeutics all-time high annual depreciation & amortization is $1.26 M

What is NeuBase Therapeutics quarterly depreciation & amortization?

The current quarterly D&A of NBSE is $250.20 K

What is the all time high quarterly D&A for NeuBase Therapeutics?

NeuBase Therapeutics all-time high quarterly depreciation & amortization is $416.90 K

What is NeuBase Therapeutics TTM depreciation & amortization?

The current TTM D&A of NBSE is $1.17 M

What is the all time high TTM D&A for NeuBase Therapeutics?

NeuBase Therapeutics all-time high TTM depreciation & amortization is $1.40 M